54
17
th
Congress of the European Society for Sexual Medicine
Industry Sessions
l
Friday 6 February 2015
LV-01
Live Surgery
08:30–12:00
Auditorium 15
Male sexual dysfunction
Chairs: David Ralph, United Kingdom
Javier Romero Otero, Spain
001 Surgeon in operation room #1
Giulio Garaffa, United Kingdom
002 Surgeon in operation room #1
Evangelos Zacharakis, United Kingdom
Chairs: Sebastian Beley, France
Daniar Osmonov, Germany
003 Surgeon in operation room #2
Dana Ohl, USA
004 Surgeon in operation room #2
Lasse Fahrenkrug, Denmark
Live broad cast from Herlev hospital
Supported by an educational grant from Coloplast A/S
RT-06
Round Table
10:30–12:00
Auditorium 10/11
Bench-to-bedside: Premature ejaculation – a trans-
lational update 2015
Chairs: Patrick Jern, Finland
Onder Yaman, Turkey
001 Central and serotoninergic origins of PE
Francois Giuliano, France
002 Genomic alterations in lifelong premature eja-
culation
Paddy Janssen, The Netherlands
003 Peripheral manipulations for premature ejacu-
lation
Ege Can Serefoglu, Turkey
004 New molecular targets in the hormonal control
of ejaculation. Where are we running?
Emmanuele A. Jannini, Italy
Supported by an educational grant from the
Menarini Group
SA-02
Satellite Symposium
12:30–14:00
Auditorium 15
ED and PE:
Disputationes
on male and female per-
spectives
Chair: Vincenzo Mirone, Italy
Opening Lecture – ED and PE: State of the art
Vincenzo Mirone, Italy
PE: Male and female perspectives
Chris McMahon, Australia
Alessandra Graziottin, Italy
ED: Male and female perspectives
Hartmut Porst, Germany
Andrea Burri, Switzerland
Q&A and closing remarks
Vincenzo Mirone, Italy
Industry sponsored satellite symposium
by the Menarini Group
RT-16
Round Table
16:00–17:15
Auditorium 15
State of the art in intracavernosal injection therapy
for PDE5-inhibitor nonresponders
Chair:
Geoffrey Hackett, United Kingdom
001 The history of penile injection therapy – past
present and future
Ronald Virag, France
002 Office work-up of PDE5-inhibitor failures
Andrea Salonia, Italy
003 Molecules for injection: Pharmacological pro-
perties and potential benefits
Stefan Arver, Sweden
004 The clinican‘s stand point: Experience with
injection therapy
Hans Joergen Kirkeby, Denmark
Supported by an educational grant from Evolan Pharma
